Poland· PL-100485125

Autnami

A metformin and linagliptin product containing linagliptinum + metformini hydrochloridum, registered in Poland by Sandoz Polska Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.

ATC A10BD11

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAutnamiATCA10BD11REGISTER NO.PL-100485125PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Metformin and linagliptin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BD11 (metformin and linagliptin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Metformin and linagliptin · ATC A10BD11

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Linagliptinum + Metformini hydrochloridum
Manufacturer
Sandoz Polska Sp. z o.o.
Country
Poland (PL)
ATC code
A10BD11
ATC class
Metformin and linagliptin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991566005

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for metformin and linagliptin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Metformin and linagliptin · interactions on record

3 records

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Metformin and linagliptin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metformin and linagliptin products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Ilinpru Combi, Linagliptin/Metformin
  • Bulgaria · Ilinpru Combi, Linatin Met
  • Cyprus · Autnami, Linagliptin/Metformin Tad
  • Czechia · Linagliptin/Metformin Sandoz, Linagliptin/Metformin Stada
  • Denmark · Glymetia, Liglifev
  • Estonia · Autnami, Linagliptin/Metformin Stada
  • Spain · Linagliptina/Metformina Cinfa, Linagliptina/Metformina Combix
  • Finland · Linagliptin/Metformin Krka, Linagliptin/Metformin Sandoz
  • United Kingdom (Northern Ireland) · Linagliptin/ Metformin Hydrochloride Torrent Pharma (Uk), Linagliptin/Metformin Hydrochloride Zentiva Pharma Uk
  • Greece · Alfalib, Linagliptin+metformin Stada
  • Croatia · Autnami, Lymerexo
  • Hungary · Autnami, Ilinpru Combi
  • Ireland · Linagliptin/Metformin Hydrochloride Rowex
  • Iceland · Jentadueto
  • Italy · Linagliptin E Metformina Eg, Linagliptin E Metformina Sandoz
  • Liechtenstein · Jentadueto
  • Lithuania · Autnami, Linagliptin/Metformin Stada
  • Latvia · Autnami, Linagliptin/Metformin Stada
  • Malta · Glymetia, Linagliptin/Metformin Clonmel
  • Netherlands · Liglifev
  • Norway · Jentadueto
  • Portugal · Metformina + Linagliptina Alter, Metformina + Linagliptina Krka
  • Slovenia · Liglipexcombi, Linagliptin/Metformin Krka
  • Slovakia · Linagliptin/Metformin Sandoz, Linagliptin/Metformin Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6bc5f864-3323-4942-a49d-4f2ab4a02006
GET /v1/drugs/6bc5f864-3323-4942-a49d-4f2ab4a02006?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "2,5 mg + 850 mg",
  "packaging": "05909991566005 ¦ Rp ¦ 160717\n60 tabl.",
  "substance": "Linagliptinum 2.5 mg + Metformini hydrochloridum 850 mg",
  "common_name": "Linagliptinum + Metformini hydrochloridum",
  "pl_product_id": "100485125",
  "pozwolenie_nr": "28892",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-02-28"
}

See everything about metformin and linagliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.